With the discovery of antibiotics nearly 100 years ago, we experienced a cultural shift that changed the medical field and made previously lethal infections manageable 1 . Additionally, the industrial revolution brought about agricultural advances that led to both an increase in per capita caloric intake and a shift in the sources of those calories 2 . While the advent of antibiotics and a shift towards greater availability of high caloric foods has considerably reduced deaths due to infectious disease and malnutrition, these cultural trends coincide both spatially and temporally with the emergence of non-communicable, chronic diseases such as obesity, diabetes, allergies, and other inflammatory disorders 3 . The spatiotemporal link between antibiotic use, changes in diet, and the rise of numerous chronic diseases led to the hypothesis that changes to the microbiome was driving these disease processes 4, 5 . However, testing this hypothesis has been difficult, due in part to a lack of an underlying framework to determine cause and effect for such a complex system 6 . One way to determine causality between microbiome and disease states has been to perform microbial transplants into germ-This article is distributed under the terms of the Creative Commons Attribution 4.0 International License http://creativecommons.org/ licenses/by/4.0/. free mice. Such studies have been conducted for obesity, liver disease, and encephalomyelitis among other disease states [7] [8] [9] .
Many clinical microbiome studies have been microbiome-wide association studies (MWAS) 10 . In these studies, authors will typically link a difference in microbiome composition between a healthy and disease population as 'dysbiosis' 11 . However, two relatively unique aspects of the microbiome make this definition of dysbiosis problematic. First, given the high levels of diversity within the microbiome, the data from the highthroughput studies often used to define dysbiosis are necessarily hypervariable. Second, there is considerable inter-individual and temporal variability in microbiome composition 12, 13 . Taken together, this means that when you examine two populations with completely stochastic metadata and no distinguishing phenotypes to define the populations, there will be significant differences in at least some components of the microbiome, even though no common form of dysbiosis exists within any one of the populations. Thus, a more concrete definition of dysbiosis is needed.
In Miller et al. 2019 14 , we specifically defined two different types of dysbiosis. Gain of function dysbiosis is that associated with infectious disease, whereby a shift in the host microbiome leads to the emergence of pathogenic bacteria and associated functions that then give rise to disease processes. Loss of function dysbiosis is defined by a shift in the host microbiome whereby bacteria that normally provided beneficial functions are lost and disease processes arise as a result. Additionally, a combination of loss and gain of function dysbiosis may be required for disease. Such is the case of chronic infection by Clostridioides difficile, whereby chronic antibiotic use can lead to the eventual overgrowth by pathogenic C. difficile 15 .
To move beyond simple MWAS studies and determine if the microbiome actually contributes to a disease or disease process is relatively straightforward. If antibiotics or some other bactericidal factor, such as those from dietary sources 16 , eliminates a disease or disease process or if microbial transplants cause a disease or disease process, then gain of function dysbiosis contributes to the disease. If the bactericidal factor leads to the emergence of a disease or disease process, or microbial transplants eliminate the disease or disease process, then loss of function dysbiosis contributes to the disease. Finally, if neither bactericidal treatments nor microbial transplants impact disease processes, then microbial dysbiosis does not contribute in any way.
In Miller et al. 14 , we focused on a specific microbial function, oxalate metabolism, that is exclusive to bacteria in the gut. Specific oxalate-degrading bacteria have been negatively correlated to both antibiotic use and urinary stone disease (USD) as determined by PCR or culture-based means and suggests that these bacteria are important for the inhibition of USD 17, 18 . For cause-effect studies of dysbiosis, it is important to identify the specific microbial functions associated with disease in order to determine if changes in the microbiome actually causes disease or is the result of the disease. Thus, in Miller et al. 14 
, we
confirmed in animal studies that both antibiotics (Cefazolin) and a high fat, high sugar diet leads to a persistent loss of oxalate-degrading bacteria and their function. Interestingly, oxalate metabolism did not return in our antibiotic-treated animals after nine days, even though much of the gut microbiota composition did, which suggests that necessary microbemicrobe interactions were not restored.
Once it has been determined that dysbiosis does contribute to a disease or disease process, then it is important to further determine the specific location where dysbiosis is most important for the disease. Given the density and diversity of microbes in the gut, many studies focus solely on dysbiosis associated with the gut microbiota, giving rise to terms such as the 'gut-brain axis', 'gut-liver axis', or 'gut-kidney axis'. However, in a recent clinical study, we found that even though patients with USD exhibited dysbiosis associated with the loss of the oxalate-degrading microbial network in the gut, all quantified metrics including association with antibiotic use, integration with metabolomic data, and association with other disease risk factors pointed to the urinary tract microbiome as having a greater level of dysbiosis than the gut microbiome 18 . Oral antibiotics can drive the loss of microbial diversity at many sites and lead to dysbiosis. Thus, for the development of bacteriotherapy designed to restore microbial functions, it is important to understand what forms of dysbiosis are most relevant for a disease.
As the biomedical microbiome field matures, it is important to move towards a mechanistic understanding of dysbiosis. This understanding can be achieved through a systematic process that asks the questions: 1) Does dysbiosis contribute to the disease?; 2) What locality of dysbiosis is most relevant to disease processes?; and 3) What microbial functions are lost or gained that contributes to the emergence of disease? Beyond MWAS studies, these questions must be addressed through a combination of bactericidal treatments/ associations and microbial transplants of whole communities. However, to refine the specific microbial mechanisms associated with disease, specifically defined consortia of bacteria must be used for transplants ideally in combination with genetic knock-outs or knock-ins. It is only through these types of studies that the microbiome can be definitively linked to specific disease processes.
